Thrivent Financial for Lutherans
ADVM

Thrivent Financial for Lutherans’s Adverum Biotechnologies ADVM Stock Holding History

Thrivent Financial for Lutherans’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,598
Closed -$651K – 2451
2021
Q1 		$651K Sell
6,598
-852
-11% -$102K ﹤0.01% 2117
2020
Q4 		$808K Sell
7,450
-1,517
-17% -$188K ﹤0.01% 1897
2020
Q3 		$924K Buy
+8,967
New +$1.34M ﹤0.01% 1610

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Thrivent Financial for Lutherans's ADVM Position: Q2 2021 in Review

Thrivent Financial for Lutherans sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 6,598 shares — an estimated $651K sold.

Thrivent Financial for Lutherans first reported a position in ADVM in Q3 2020 and held it in 3 quarters. The position peaked at $924K in Q3 2020. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • Thrivent Financial for Lutherans reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 6,598 Adverum Biotechnologies shares in Q2 2021, an estimated $651K.
  • Thrivent Financial for Lutherans first reported a position in Adverum Biotechnologies in Q3 2020 and held it in 3 quarters.
  • Thrivent Financial for Lutherans's Adverum Biotechnologies position peaked at $924K in Q3 2020.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2021, filed 19 Aug 2021.